Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.65 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.65 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.65 |
| ▸ | CA2 | P00918 | 2/20 | 0.60 |
| ▸ | HTR6 | P50406 | 1/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.60 |
| ▸ | HPGD | P15428 | 2/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.57 |
| ▸ | NPC1 | O15118 | 1/20 | 0.57 |
| ▸ | RAB9A | P51151 | 1/20 | 0.57 |
| ▸ | LMNA | P02545 | 2/20 | 0.56 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.54 |
| ▸ | HTT | P42858 | 1/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.54 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.54 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15606965 | 1.00 | POLB (0.65) | POLBESR2MTNR1ACA2HTR6 | |
| SCHEMBL8367125 | 0.83 | POLB (0.75) | POLBESR2MTNR1ACA2ALDH1A1 | |
| SCHEMBL18358970 | 0.83 | POLB (0.75) | POLBESR2MTNR1ACA2ALDH1A1 | |
| SCHEMBL9413231 | 0.83 | CA2 (0.62) | POLBESR2MTNR1ACA2ALDH1A1 | |
| SCHEMBL9695874 | 0.82 | MTNR1A (0.65) | POLBESR2MTNR1ACA2ALDH1A1 | |
| SCHEMBL7745204 | 0.81 | POLB (0.60) | POLBESR2MTNR1ACA2ALDH1A1 | |
| SCHEMBL13532085 | 0.81 | POLB (0.60) | POLBESR2MTNR1ACA2ALDH1A1 | |
| SCHEMBL16419112 | 0.81 | POLB (0.60) | POLBESR2MTNR1ACA2ALDH1A1 | |
| SCHEMBL10864903 | 0.80 | POLB (0.97) | POLBESR2MTNR1ACA2ALDH1A1 | |
| SCHEMBL29353196 | 0.80 | POLB (0.97) | POLBESR2MTNR1ACA2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 89 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12291533-B2 | Substituted fused pyrimidine compounds and uses thereof | NORTHWESTERN UNIVERSITY (US) | 2025-05-06 | — | — | US | disclosed |
| US-20200283444-A1 | SUBSTITUTED FUSED PYRIMIDINE COMPOUNDS AND USES THEREOF | NORTHWESTERN UNIVERSITY | 2020-09-10 | — | — | US | disclosed |
| US-20170340636-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF AUTOPHAGY | UNIV TEXAS (US) | 2017-11-30 | — | — | US | disclosed |
| EP-1768970-B1 | SULFAMATE AND SULFAMIDE DERIVATIVES FOR THE TREATMENT OF EPILEPSY AND RELATED DISORDERS | JANSSEN PHARMACEUTICA NV (BE) | 2016-03-09 | — | — | EP | disclosed |
| US-20150031878-A1 | DERIVATIVES OF DOCOSAHEXAENOYLETHANOLAMIDE AND USES THEREOF | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | 2015-01-29 | — | — | US | disclosed |
| US-8937096-B2 | Use of benzo-fused heterocyle sulfamide derivatives for the treatment of mania and bipolar disorder | JANSSEN PHARMACEUTICA NV (BE) | 2015-01-20 | — | — | US | disclosed |
| US-8853263-B2 | Co-therapy for the treatment of epilepsy and related disorders | JANSSEN PHARMACEUTICA NV (BE) | 2014-10-07 | — | — | US | disclosed |
| EP-1968572-B1 | USE OF BENZO-FUSED HETEROCYCLE SULFAMIDE DERIVATIVES FOR THE TREATMENT OF SUBSTANCE ABUSE AND ADDICTION | JANSSEN PHARMACEUTICA NV (BE) | 2014-08-06 | — | — | EP | disclosed |
| EP-2276481-B1 | USE OF BENZO-FUSED HETEROCYCLE SULFAMIDE DERIVATIVES FOR THE TREATMENT OF ANXIETY | JANSSEN PHARMACEUTICA NV (BE) | 2014-07-30 | — | — | EP | disclosed |
| US-8716231-B2 | Use of benzo-fused heterocycle sulfamide derivatives for the treatment of pain | JANSSEN PHARMACEUTICA NV (BE) | 2014-05-06 | — | — | US | disclosed |
| WO-2007075752-A1 | USE OF BENZO-FUSED HETEROCYCLE SULFAMIDE DERIVATIVES FOR THE TREATMENT OF PAIN | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-07-05 | — | — | WO | disclosed |
| EP-1768970-A1 | SULFAMATE AND SULFAMIDE DERIVATIVES FOR THE TREATMENT OF EPILEPSY AND RELATED DISORDERS | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-04-04 | — | — | EP | disclosed |
| US-20060041008-A1 | Novel sulfamate and sulfamide derivatives useful for the treatment of epilepsy and related disorders | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-02-23 | — | — | US | disclosed |
| WO-2006007436-A1 | SULFAMATE AND SULFAMIDE DERIVATIVES FOR THE TREATMENT OF EPILEPSY AND RELATED DISORDERS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2006-01-19 | — | — | WO | disclosed |
| WO-2006007435-A1 | SULFAMATE AND SULFAMIDE DERIVATIVES FOR THE TREATMENT OF EPILEPSY AND RELATED DISORDERS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2006-01-19 | — | — | WO | disclosed |
| US-20050282887-A1 | Novel sulfamate and sulfamide derivatives useful for the treatment of epilepsy and related disorders | JANSSEN PHARMACEUTICA NV (BE) | 2005-12-22 | — | — | US | disclosed |
| US-6756373-B1 | SUCH AS 5-(2-BUTOXY-5-IODO-3-PYRIDINYL)-3-ETHYL-2-(2-METHOXY-ETHYL)-2,6-DIHYDRO-7H -PYRAZOLO(4,3-D)PYRIMIDIN-7-ONE; CYCLIC GUANOSINE 3',5'-MONOPHOSPHATE PHOSPHODIESTERASE INHIBITORS; ERECTILE DYSFUNCTION | PFIZER INC. | 2004-06-29 | — | — | US | disclosed |
| EP-1222190-A1 | 5-(2-SUBSTITUTED-5-HETEROCYCLYLSULPHONYLPYRID-3-YL)-DIHYDROPYRAZOLO[4,3-D]PYRIMIDIN-7-ONES AS PHOSPHODIESTERASE INHIBITORS | Pfizer Limited (GB) | 2002-07-17 | — | — | EP | disclosed |
| WO-2001027112-A1 | 5-(2-SUBSTITUTED-5-HETEROCYCLYLSULPHONYLPYRID-3-YL)-DIHYDROPYRAZOLO[4,3-D]PYRIMIDIN-7-ONES AS PHOSPHODIESTERASE INHIBITORS | PFIZER LIMITED (GB) | 2001-04-19 | — | — | WO | disclosed |
| EP-0586866-A2 | 1,4,-Benzodioxane derivatives with pharmacologic properties | MERCK PATENT GmbH (DE) | 1994-03-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200283444-A1 | SUBSTITUTED FUSED PYRIMIDINE COMPOUNDS AND USES THEREOF | GBA3, GBA1, GBA2 | POLB 1069/4885ESR2 4838/4885MTNR1A 4350/4885 |
| US-20170340636-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF AUTOPHAGY | ATG7, BECN1, ULK1 | POLB 2817/4885ESR2 1940/4885MTNR1A 1895/4885 |
| US-20060041008-A1 | Novel sulfamate and sulfamide derivatives useful for the treatment of epilepsy and related disorders | SULT2A1, STS, GRIK5 | POLB 4415/4885ESR2 1341/4885MTNR1A 734/4885 |
| US-20050282887-A1 | Novel sulfamate and sulfamide derivatives useful for the treatment of epilepsy and related disorders | SULT2A1, STS, GRIK5 | POLB 4415/4885ESR2 1341/4885MTNR1A 734/4885 |
| US-20150031878-A1 | DERIVATIVES OF DOCOSAHEXAENOYLETHANOLAMIDE AND USES THEREOF | GAP43, DGAT2, DCX | POLB 1719/4885ESR2 1969/4885MTNR1A 2491/4885 |
| US-12291533-B2 | Substituted fused pyrimidine compounds and uses thereof | GBA3, GBA1, GBA2 | POLB 1069/4885ESR2 4838/4885MTNR1A 4350/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.